Medical management of Crohn's disease

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 16, 2011, Pages 2505-2525

  Cottone, Mario ^a   Renna, Sara ^a   Orlando, Ambrogio ^a   Mocciaro, Filippo ^b  

^a UNIVERSITY OF PALERMO   (Italy)

^b Gastroenterology Unit   (Italy)

Author keywords

Crohns; medical management; therapy

Indexed keywords

4 NITROIMIDAZOLE; ACETYLSALICYLIC ACID; ADALIMUMAB; AMINOSALICYLIC ACID; AZATHIOPRINE; BUDESONIDE; CERTOLIZUMAB PEGOL; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MACROLIDE; MERCAPTOPURINE; METHOTREXATE; METRONIDAZOLE; MYCOPHENOLIC ACID; PREDNISOLONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RIFABUTIN; RIFAXIMIN; STEROID; THALIDOMIDE; TOCILIZUMAB; TUMOR NECROSIS FACTOR ANTIBODY; UNINDEXED DRUG;

ABDOMINAL PAIN; ACNE; ADD ON THERAPY; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC THERAPY; ARTHRALGIA; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COMPARATIVE STUDY; CROHN DISEASE; DIABETES MELLITUS; DISEASE SEVERITY; DRUG FEVER; DRUG INDUCED HEADACHE; DYSPEPSIA; ENTERITIS; FATIGUE; FISTULA; GLAUCOMA; HEPATITIS; HIRSUTISM; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE MUCOSA; IRRITABLE COLON; LEUKOCYTE; LIVER TOXICITY; MOON FACE; MYALGIA; NAUSEA; OSTEOPOROSIS; PANCREATITIS; PATIENT MONITORING; QUESTIONNAIRE; REMISSION; REVIEW; SCORING SYSTEM; SEPSIS; SIDE EFFECT; TERATOGENICITY; THROMBOCYTOPOIESIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADRENAL CORTEX HORMONES; AMINOSALICYLIC ACIDS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL AGENTS; BONE MARROW TRANSPLANTATION; BUDESONIDE; CROHN DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINES; METHOTREXATE; PURINES; REMISSION INDUCTION; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80054066689     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.609556     Document Type: Review

References (188)

1. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976;70:439-44
2. Winship DH, Summers RW, Singleton JW, et al. National Cooperative Crohn's Disease Study: study design and conduct of the study. Gastroenterology 1979;77:829-42 (Pubitemid 9257851)
3. Van Assche G, Dignass A, Panes J, et al. European Crohn's and Colitis Organisation (ECCO). The second European evidence-based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis 2010;4:7-27
4. Orlando A, Armuzzi A, Papi C, et al. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: the use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease. Dig Liver Dis 2011;43:1-20
5. Harvey RF, Bradshaw JM. A simple index of Crohn's disease activity. Lancet 1980;1:514
6. Vermeire S, Schreiber S, Sandborn WJ, et al. Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity. Clin Gastroenterol Hepatol 2010;4:357-63
7. Irvine EJ. Usual therapy improves perianal Crohn's disease as measured by a new disease activity index. McMaster IBD Study Group. J Clin Gastroenterol 1995;20:27-32
8. Van Assche G, Dignass A, Reinisch W, et al. European Crohn's and Colitis Organisation (ECCO). The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: special situations. J Crohns Colitis 2010;4:63-101
9. Rutgeerts P, Geboes K, Vantrappen G, et al. Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut 1984;25:665-72 (Pubitemid 14122134)
10. Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990;99:956-63 (Pubitemid 20338451)
11. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 2002;359:1541-9 (Pubitemid 34621118)
12. Rutgeerts P, D'Haens GR, Van Assche G, et al. Adalimumab induces and maintains mucosal healing in patients with moderate to severe ileocolonic crohn's disease -first results of the extend trial. DDW 2009;751e
13. Frøslie KF, Jahnsen J, Moum BA, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007;133:412-22 (Pubitemid 47187355)
14. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994;106:287-96 (Pubitemid 24041204)
15. Sostegni R, Daperno M, Scaglione N, et al. Crohn's disease: monitoring disease activity. Aliment Pharmacol Ther 2003;17(Suppl 2):11-17
16. Svartz N. Sulfasalazine: II. Some notes on the discovery and development of salazopyrin. Am J Gastroenterol 1988;83:497-503
17. Baron JH, Connel AM, Lennard-Jones JE, et al. Sulphasalzine and salicylazosulphadimidine in ulcerative colitis. Lancet 1962;1:1094-6
18. Misiewicz J, Lennard-Jones JE, Connell AM, et al. Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis. Lancet 1965;1:185-8
19. Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn's disease study: results of drug treatment. Gastroenterology 1979;77:847-69 (Pubitemid 9242048)
20. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984;86:249-66 (Pubitemid 14218578)
21. Azad Kahn AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977;2:892-5
22. Van Hees PAM, Bakker JH, Van Tongeren JHM. Effect of sulphapyridine, 5-aminosalicylic acid and placebo in patients with idiopathic proctitis: study to determine the active therapeutic moiety of sulphasalazine. Gut 1980;21:632-5 (Pubitemid 10018354)
23. Hanauer SB, Stromberg U. Oral pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol 2004;2:379-88 (Pubitemid 38561234)
24. Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16 week trial. Gastroenterology 1993;104:1293-301 (Pubitemid 23235401)
25. Nordic Research, Inc. Clinical research report: efficacy and safety of oral Pentasa in the treatment of active Crohn's disease. 1991
26. Hoechst Marion Roussel, Inc. Clinical study report: efficacy and safety of oral Pentasa in the treatment of active Crohn's disease. 1997
27. Singleton J. Second trial of mesalamine therapy in the treatment of active Crohn's disease. Gastroenterology 1994;107:632-3 (Pubitemid 24233348)
28. Thomsen OO, Cortot A, Jewell D, et al. A comparison of budesonide and mesalamine for active Crohn's disease. N Engl J Med 1998;339:370-4 (Pubitemid 28363799)
29. Tromm A, Bunganic I, Tomsova E, et al. Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease. Gastroenterology 2011;140:425-34
30. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010;4:28-62
31. Ford AC, Kane SV, Khan KJ, et al. Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis. Am J Gastroenterol 2011;106:617-29
32. Rahimi R, Nikfar S, Rezaie A, et al. A meta-analysis of broad-spectrum antibiotic therapy in patients with active Crohn's disease. Clin Ther 2006;28:1983-8 (Pubitemid 46215747)
33. Borgaonkar MR, MacIntosh DG, Fardy JM. A meta-analysis of antimycobacterial therapy for Crohn's disease. Am J Gastroenterol 2000;95:725-9 (Pubitemid 30123910)
34. Selby W, Pavli P, Crotty B, et al. Two year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. Gastroenterology 2007;132:2313-19 (Pubitemid 46890859)
35. Prantera C, Lochs H, Campieri M, et al. Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther 2006;23:1117-25 (Pubitemid 43779351)
36. Khan KJ, Ullman TA, Ford AC, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011;106:661-73
37. Fahey JV, Guyer PM, Munck A. Mechanisms of anti-inflammatory actions of glucocorticoids. Advances in inflammatory research. Raven Press; New York: 1981
38. Benchimol EI, Seow CH, Steinhart AH, et al. Traditional corticosteroids for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2008;2:CD006792
39. Singleton JW, Law DH, Kelley ML Jr, et al. National Cooperative Crohn's Disease Study: adverse reactions to study drugs. Gastroenterology 1979;77:870-82 (Pubitemid 9242049)
40. Brattsand R. Overview of newer glucocorticoid preparations for inflammatory bowel disease. Can J Gastroenterol 1990;4:407-14
41. Thomsen OO, Cortot A, Jewell D, et al. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. N Engl J Med 1998;339:370-4 (Pubitemid 28363799)
42. Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994;331:842-5 (Pubitemid 24289711)
43. Gross V, Andus T, Caesar I, et al. Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. German/Austrian Budesonide Study Group. Eur J Gastroenterol Hepatol 1996;8:905-9 (Pubitemid 26319395)
44. Campieri M, Ferguson A, Doe W, et al. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut 1997;41:209-14 (Pubitemid 27395924)
45. Bar-Meier S, Chowers Y, Lavy A, et al. Budesonide versus prednisone in the treatment of active Crohn's disease. Gastroenterology 1998;115:835-40 (Pubitemid 28452930)
46. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 1994;331:836-41 (Pubitemid 24289710)
47. Tremaine WJ, Hanauer SB, Katz S, et al. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States. Am J Gastroenterol 2002;97:1748-54 (Pubitemid 34761401)
48. D'Haens G, Verstraete A, Cheyns K, et al. Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn's disease. Aliment Pharmacol Ther 1998;12:419-24 (Pubitemid 28247512)
49. Escher JC. European Collaborative Research Group on Budesonide in Paediatric IBD. Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial. Eur J Gastroenterol Hepatol 2004;16:47-54 (Pubitemid 39043702)
50. Levine A, Weizman Z, Broide E, et al. A comparison of budesonide and prednisone for the treatment of active pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2003;36:248-52 (Pubitemid 39272978)
51. Tursi A, Giorgetti GM, Brandimarte G, et al. Beclomethasone dipropionate for the treatment of mild-to-moderate Crohn's disease: an open-label, budesonide-controlled, randomized study. Med Sci Monit 2006;12:PI29-32 (Pubitemid 43854433)
52. Van Ierssel AJ, Van der Sluys Veer A, Verspaget HW, et al. Budesonide and prednisolone suppress peripheral blood natural killer cells in Crohn's disease. Aliment Pharmacol Ther 1995;9:173-8
53. Seow CH, Benchimol EI, Griffiths AM, et al. Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2008;3:CD000296
54. Munkholm P, Langholz E, Davidsen M, et al. Frequency of glucocorticoid resistance and dependency in Crohn's disease Gut 1994;35:360-2
55. Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2009;4:CD000545
56. Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980;302:981-7 (Pubitemid 10125406)
57. Khan KJ, Dubinsky MC, Ford AC, et al. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011;106:630-42
58. Hindorf U, Johansson M, Eriksson A, et al. Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther 2009;29:654-61
59. Arora S, Katkov W, Cooley J, et al. Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial. Hepatogastroenterology 1999;46:1724-9 (Pubitemid 29366332)
60. Mate-Jimenez J, Hermida C, Cantero-Perona J, et al. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000;12:1227-33
61. Oren R, Moshkowitz M, Odes S, et al. Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial. Am J Gastroenterol 1997;92:2203-9
62. Ardizzone S, Bollani S, Manzionna G, et al. Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study. Dig Liver Dis 2003;35:619-27 (Pubitemid 41110872)
63. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995;332:292-7
64. Loper-Cubero SO, Sullivan K, MacDonald G. Course of Crohn's disease after allogenic marrow transplantation. Gastroenterology 1998;114:433-40
65. Cassinotti A, Annaloro C, Ardizzone S, et al. Autologous haematopoietic stem cell trasplantation without CD34+ cell selection in refractory Crohn's disease. Gut 2008;57:211-17 (Pubitemid 351158049)
66. Neurath MF, Wanitschke R, Peters M, et al. Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease. Gut 1999;44:625-8 (Pubitemid 29195908)
67. Palaniappan S, Ford AC, Greer D, et al. Mycophenolate mofetil therapy for refractory inflammatory bowel disease. Inflamm Bowel Dis 2007;13:1488-92
68. Stallmach A, Wittig BM, Moser C, et al. Safety and efficacy of intravenous pulse cyclophosphamide in acute steroid refractory inflammatory bowel disease. Gut 2003;52:377-82 (Pubitemid 36250057)
69. Srinivasan R, Akobeng AK. Thalidomide and thalidomide analogues for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2009;2:CD007350
70. Zheng CF, Xu JH, Huang Y, et al. Treatment of pediatric refractory Crohn's disease with thalidomide. World J Gastroenterol 2011;17:1286-91
71. Summers RW, Elliott DE, Urban JF Jr, et al. Trichuris suis therapy in Crohn's disease. Gut 2005;54:87-90 (Pubitemid 40007223)
72. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35
73. Hanauer SB, Sandborn VJ, Rutgeers P, et al. Human anti-tumor necrosis factor monocolonal antibodies (adalimumab) in Crohn's disease: the classic I trial. Gastroenterology 2006;130:322-33
74. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65 (Pubitemid 46108762)
75. Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonistis in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008;6:644-53 (Pubitemid 351783447)
76. Schreiber S, Rutgeerts P, Fedorak RN, et al. CDP870 Crohn's Disease Study Group. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005;129:807-18 (Pubitemid 41242673)
77. Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011;106:644-59
78. Lemann M, Mary JY, Duclos B, et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 2006;130:1054-61
79. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95
80. Lofberg R, Louis E, Reinisch W, et al. Adalimumab effectiveness in TNF antagonist-naive patients and in infliximab non responders with Crohn's disease: results from the Care Study. Am J Gastroenterol 2008;103(Suppl 1):S418
81. Sandborn WJ, Rutgeers P, Enns R, et al. Adalimumab induction therapy for Crohn's disease previously treated with infiximab: a randomized trial. Ann Intern Med 2007;146:829-38 (Pubitemid 351650483)
82. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357:228-38 (Pubitemid 47080387)
83. Colombel JF, Hebuterne X. Endoscopic mucosal improvement in patients with active Crohn's disease treated with certolizumab pegol: first results of the MUSIC clinical trial [abstract]. Am J Gastroenterol 2008;103:A1107
84. Sandborn WJ, Vermeire S, D'Haens G, et al. Welcome: a randomized, double-blind, controlled trial comparing certolizumab pegol 400 mg every 2 weeks with every 4 weeks for maintenance of response and remission in patients with moderate to severe Crohn's Disease with secondary failure to infliximab. Gastroenterology 2009;136(Suppl 1):A47
85. Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009;15:1295-301
86. Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol 2011;9:30-5
87. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008;371:660-7 (Pubitemid 351284485)
88. Schreiber S, Reinisch W, Colombel JF. Early Crohn's disease shows high levels of remission to therapy with adalimumab: sub-analysis of CHARM. Gastroenterology 2007;132(Suppl 2):A985
89. Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn's disease. Gastroenterology 2006;130:650-6
90. Korzenick JR, Dieckgraefe BK, Valentine JF, et al. Salmograstin for active Crohn's disease. N Engl J Med 2005;352:2193-201
91. Feagan BG, Anderson F, Radford-Smith GL, et al. Efficacy and safety of salmograstin in moderate to severe Crohn's disease: results of NOVEL 4 phase multicenter study. Gastroenterology 2007;132(Suppl 2):A103
92. Valentine JF, Fedorak RN, Feagan B, et al. Steroid sparing properties of sarmograstin in patients with corticosteroid dependent Crohn's disease: a randomized double blind placebo controlled phase 3 study. Gut 2009;58:1354-62
93. Van Deventer SJH, Elson C, Fedorak R. Multiple doses of intravenous interleukin 10 in steroid refractory Crohn's disease. Gastroenterology 1997;113:383-9 (Pubitemid 27351761)
94. Colombel JF, Rutgeerts P, Malchow H, et al. Interleukin 10 in the prevention of postoperative recurrence. Gut 2001;49:42-6
95. Ito H, Takazoe M, Fukuda Y, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004;126:989-96 (Pubitemid 38451170)
96. Burakoff R, Barish CF, Riff D, et al. A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease. Inflamm Bowel Dis 2006;12:558-65 (Pubitemid 43977736)
97. Mannon PJ, Fuss IJ, Mayer L, et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004;351:2069-79 (Pubitemid 39482500)
98. Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate to severe Crohn's disease. Gastroenterology 2008;135:1130-41
99. Reinisch W, Hommes DW, Van Assche G, et al. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease. Gut 2006;55:1138-44 (Pubitemid 44085682)
100. Hommes DW, Mikhajlova TL, Stoinov S, et al. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut 2006;55:1131-7 (Pubitemid 44085681)
101. Reinisch W, de Villiers W, Bene L, et al. Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis 2010;16:233-42
102. Kasran A, Boon A, Wortel H. Safety and tolerability of antagonist anti-human CD40 Mab ch5D12 in patients with moderate to severe Crohn's disease. Aliment Pharmacol Ther 2005;22:1111-22
103. Maxwell L, Singh JA. Abatacept for rheumatoid arthritis. Cochrane Database Syst Rev 2009;4:CD007277
104. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med 2003;348:24-32
105. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial Group; Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group. N Engl J Med 2005;353:1912-25 (Pubitemid 41565956)
106. Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 2007;132:1672-83 (Pubitemid 46695722)
107. Sands BE, Kozarek R, Spainhour J, et al. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab. Inflamm Bowel Dis 2007;13:2-11 (Pubitemid 46080003)
108. Feagan BG, Greenberg GR, Wild G, et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol 2008;6:1370-7
109. Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, et al. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 1998;114:1133-42 (Pubitemid 28243898)
110. Yacyshyn BR, Barish C, Goff J, et al. Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease. Aliment Pharmacol Ther 2002;16:1761-70
111. Yacyshyn BR, Chey WY, Goff J, et al. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut 2002;51:30-6 (Pubitemid 34717740)
112. Yacyshyn B, Chey WY, Wedel MK, et al. A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of a subjects with active Crohn's disease. Clin Gastroenterol Hepatol 2007;5:215-20 (Pubitemid 46216935)
113. Keshav S, Wolf D, Katz S, et al. CCX282-B, an orally active inhibitor of chemokine receptor CCR9, in a randomized, double-blind, placebo-controlled phase 2 study in moderate to severe Crohn's disease. Gut 2006;A22:OP-G-93
114. Hommes D, Van de blink B, Plasse T, et al. Inhibition of stress activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 2002;122:7-14 (Pubitemid 34049188)
115. Schreiber S, Feagan B, D'Haens G, et al. Oral p38 mitogen activated protein kinase inibition with BIRB 796 for active Crohn's disease:a randomized double blind placebo controlled trial. Clin Gastroenterol Hepatol 2006;4:325-34
116. Lennard-Jones JE. Sulphasalazine in asymptomatic Crohn's disease. A multicentre trial. Gut 1977;18:69-72
117. Camma C, Giunta M, Rosselli M, Cottone M. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology 1997;113:1465-73 (Pubitemid 27461232)
118. Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically induced remission in Crohn's disease [review]. Cochrane Libr 2009;4
119. Mahmud N, Kamm MA, Dupas JL, et al. Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre study. Gut 2001;49:552-6 (Pubitemid 32896987)
120. Patel H, Barr Jeejeebhoy. Renal effects of long-term treatment with 5-aminosalicylic acid. Can J Gastroenterol 2009;23:170-6
121. Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the committee on safety of medicines. Gut 2002;51:536-9
122. Chakraborty TK, Bhatia D, Heading RC, et al. Salicylate induced exacerbation of ulcerative colitis. Gut 1987;28:613-15 (Pubitemid 17073230)
123. Feller M, Huwiler K, Schoepfer A, et al. Long-term antibiotic treatment for Crohn's disease: systematic review and meta-analysis of placebo-controlled trials. Clin Infect Dis 2010;50:473-80
124. Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995;108:1617-21
125. Rutgeerts P, Van Assche G, Vermeire S, et al. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, doubleblind, placebo-controlled trial. Gastroenterology 2005;128:856-61 (Pubitemid 40523538)
126. Steinhart AH, Ewe K, Griffiths AM, et al. Traditional corticosteroids for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2008;4:CD006792
127. Brignola C, De Simone G, Belloli C, et al. Steroid treatment in active Crohn's disease: a comparison between two regimens of different duration. Aliment Pharmacol Ther 1994;8:465-8 (Pubitemid 24257565)
128. Benchimol EI, Seow CH, Otley AR, et al. Budesonide for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009;1:CD002913
129. Prefontaine E, Sutherland LR, Macdonald JK, et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009;1:CD000067
130. Lemann M, Mary JY, Colombel J-F, et al. A randomized, double blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 2005;128:1812-18 (Pubitemid 40824692)
131. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009;374:1617-25
132. Bebb JR, Logan RP. Review article: does the use of immunosuppressive therapy in inflammatory bowel disease increase the risk of developing lymphoma? Aliment Pharmacol Ther 2001;15:1843-9 (Pubitemid 34014338)
133. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000;342:1627-32 (Pubitemid 30341531)
134. Oren R, Moshkowitz M, Odes S, et al. Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial. Am J Gastroenterol 1997;92:2203-9
135. Feagan BG, McDonald JWD, Panaccione R, et al. A randomized trial of methotrexate in combination with infliximab for the treatment of Crohn's disease. Presented at Digestive Disease Week, 17-22 May 2008, San Diego, CA, USA
136. Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44:265-7 (Pubitemid 46175082)
137. Shale MS, Kanfer E, Panaccione R, et al. Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut 2008;57:1639-41
138. Ochenrider MG, Patterson DJ, Aboulafia DM. Hepatosplenic T-cell lymphoma in a young man with Crohn's disease: case report and literature review. Clin Lymphoma Myeloma Leuk 2010;10:144-8
139. Panaccione R, Colombel GF, Sandborn WJ, et al. Adalimumab sustains clinical remission and overall clinical benefit after 2 years therapy for Crohn's disease. Aliment Pharmacol Ther 2010;31:1296-309
140. Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre color study. Gut 2009;58:501-8
141. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009;58:492-500
142. Reinisch W, Panes J, Lemann M, et al. A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease. Am J Gastroenterol 2008;103:2284-92
143. Pena-Rossi C, Schreiber S, Golubovic G, et al. Clinical trial: a multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon-beta-1a in moderately active ulcerative colitis. Aliment Pharmacol Ther 2008;28:758-6
144. Renna S, Camma C, Modesto I, et al. M. Meta-analysis of the placebo rates of clinical relapse and severe endoscopic recurrence in postoperative Crohn's disease. Gastroenterology 2008;135:1500-9
145. Cottone M, Rosselli M, Orlando A, et al. Smoking habits and recurrence in Crohn's disease. Gastroenterology 1994;106:643-8 (Pubitemid 24064330)
146. Reese GE, Nanidis T, Borysiewicz C, et al. The effect of smoking after surgery for Crohn's disease: a meta-analysis of observational studies. Int J Colorectal Dis 2008;23:1213-21
147. Simillis C, Yamamoto T, Reese GE, et al. A meta-analysis comparing incidence of recurrence and indication for reoperation after surgery for perforating versus nonperforating Crohn's disease. Am J Gastroenterol 2008;103:196-205
148. Greenstein AJ, Lachman P, Sachar DB, et al. Perforating and non-perforating indications for repeated operations in Crohn's disease: evidence for two clinical forms. Gut 1988;29:588-92
149. Yamamoto T. Factors affecting recurrence after surgery for Crohn's disease. World J Gastroenterol 2005;11:3971-9 (Pubitemid 41235590)
150. Doherty G, Bennett G, Patil S, et al. Intervention for prevention of postoperative recurrence of Crohn's disease. Cochrane Database Syst Rev 2009
151. Lochs H, Mayer M, Fleig WE, et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology 2000;118:264-73 (Pubitemid 30067499)
152. Cottone M, Camma C. Mesalamine and relapse prevention in Crohn's disease. Gastroenterology 2000;119:597 (Pubitemid 30622008)
153. D'Haens GR, Vermeire S, Van Assche G, et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroenterology 2008;135:1123-9
154. Hanauer SB, Korelitz BI, Rutgeerts P, et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004;127:723-9 (Pubitemid 39208405)
155. Peyrin-Biroulet L, Deltenre P, Ardizzone S, et al. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am J Gastroenterol 2009;104:2089-96
156. Reinisch W, Angelberger S, Petritsch W, et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. Gut 2010;59:752-9
157. Van Gossum A, Dewit O, Louis E, et al. Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after lleo-caecal resection. Inflamm Bowel Dis 2007;13:135-42 (Pubitemid 46806221)
158. Marteau P, Lemann M, Seksik P, et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Gut 2006;55:842-7 (Pubitemid 43764556)
159. Prantera C, Scribano ML, Falasco G, et al. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 2002;51:405-9
160. Regueiro M, Schraut W, Baidoo L, et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 2009;136:441-50
161. Sorrentino D, Terrosu G, Avellini C, et al. Infliximab with low-dose methotrexate for prevention of postsurgical recurrence of ileocolonic Crohn disease. Arch Intern Med 2007;167:1804-7 (Pubitemid 47403070)
162. Haggett PJ, Moore NR, Shearman JD, et al. Pelvic and perineal complications of Crohn's disease: assessment using magnetic resonance imaging. Gut 1995;36:407-10
163. Skalej M, Makowiec F, Weinlich M, et al. Magnetic resonance imaging in perianal Crohn's disease. Dtsch Med Wochenschr 1993;118:1791-6 (Pubitemid 24000184)
164. Koelbel G, Schmiedl U, Majer MC, et al. Diagnosis of fistulae and sinus tracts in patients with Crohn disease: value of MR imaging. AJR Am J Roentgenol 1989;152:999-1003 (Pubitemid 19125130)
165. Van Bodegraven AA, Sloots CE, Felt-Bersma RJ, et al. Endosonographic evidence of persistence of Crohn's disease-associated fistulas after infliximab treatment, irrespective of clinical response. Dis Colon Rectum 2002;45:39-46 (Pubitemid 34072750)
166. Sloots CE, Felt-Bersma RJ, Poen AC, et al. Assessment and classification of fistula-in-ano in patients with Crohn's disease by hydrogen peroxide enhanced transanal ultrasound. Int J Colorectal Dis 2001;16:292-7 (Pubitemid 32927001)
167. Orsoni P, Barthet M, Portie F, et al. Prospective comparison of endosonography, magnetic resonance imaging and surgical findings in anorectal fistula and abscess complicating Crohn's disease. Br J Surg 1999;86:360-4 (Pubitemid 29145923)
168. Parks AG, Gordon PH, Hardcastle J. A classification of fistula-in-ano. Br J Surg 1976;63:1-12
169. Bell SJ, Williams AB, Wiesel P, et al. The clinical course of fistulating Crohn's disease. Aliment Pharmacol Ther 2003;17:1145-51 (Pubitemid 36605751)
170. Bernstein LH, Frank MS, Brandt LJ, et al. Healing of perineal Crohn's disease with metronidazole. Gastroenterology 1980;79:357-65 (Pubitemid 10046383)
171. Brandt LJ, Bernstein LH, Boley SJ, et al. Metronidazole therapy for perineal Crohn's disease: a follow-up study. Gastroenterology 1982;83:383-7 (Pubitemid 12078222)
172. Jakobovits J, Schuster MM. Metronidazole therapy for Crohn's disease and associated fistulae. Am J Gastroenterol 1984;79:533-40 (Pubitemid 14091511)
173. Thia KT, Mahadevan U, Feagan BG, et al. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis 2009;15:17-24
174. Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995;123:132-42
175. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405 (Pubitemid 29205403)
176. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-85 (Pubitemid 38252535)
177. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007;357:239-50 (Pubitemid 47080388)
178. Gaertner WB, Decanini A, Meligren A, et al. Does infliximab infusion impact results of operative treatment for Crohn's perianal fistulas? Dis Colon Rectum 2007;50:1754-60 (Pubitemid 350077116)
179. Hyder SA, Travis SP, Jewell DP, et al. Fisulating anal Crohn's disease: results of combined surgical and infliximab treatment. Dis Colon Rectum 2006;49:1837-41 (Pubitemid 44853440)
180. Topstad DR, Panaccion R, Heine JA, et al. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improving healing rate in fistulising anorectal Crohn's disease. A single center experience. Dis Colon Rectum 2003;46:577-83 (Pubitemid 36576412)
181. Van der Hagen SJ, Baeten CG, Soeters PB, et al. Anti-TNF-alpha (infliximab) used as induction treatment in case of active proctitis in a multistep strategy followed by definitive surgery of complex anal fistulas in Crohn's disease: a preliminary report. Dis Colon Rectum 2005;48:758-67 (Pubitemid 40880724)
182. Lichtenstein GR, Diamond RH, Wagner CL, et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther 2009;30:210-26
183. Sokol H, Seksik P, Carrat F, et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut 2010;59:1363-8
184. Moss AC, Kim KJ, Fernandez-Becker N, et al. Impact of concomitant immunomodulator use on long-term outcomes in patients receiving scheduled maintenance infliximab. Dig Dis Sci 2010;55:1413-20
185. Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010;138:463-8
186. D'Haens G, Geboes K, Rutgeerts P. Endoscopic and histologic healing of Crohn's ileo colitis with azathioprine. Gastrointest Endosc 1999;50:667-71 (Pubitemid 29518050)
187. D'Haens GR, Noman M, Baert F, et al. Endoscopic healing after infliximab treatment for Crohn's disease provides a longer time to relapse. Gastroenterology 2002;122:776(A)
188. Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006;63:433-42 (Pubitemid 43261469)